StockData

Eton Pharmaceuticals vs Xeris Biopharma

ETON and XERS side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How ETON and XERS compare

Xeris Biopharma is the larger company, worth 1.7 times as much as Eton Pharmaceuticals ($3.1B against $1.8B).

Eton Pharmaceuticals grew revenue faster over the last twelve months (81.5% versus 36.3% for Xeris Biopharma).

Eton Pharmaceuticals keeps more of each dollar of sales as profit, with a net margin of 12.0% compared with −5.1% at Xeris Biopharma.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricETONXERS
Size and price
Market cap$1.8B$3.1B
Share price$63.65$16.80
Change, 1 year276%134%
Change, 5 years1408%674%
Beta (5Y)−0.440.27
Employees44435
StockData Score
Total score1010
Valuation score00
Growth score34 (better)
Performance score4 (better)3
Health score33
Dividend score00
Valuation
P/E163×–
P/S17.2×9.1× (better)
P/B39.1×–
EV/EBITDA87.3×84.2× (better)
P/FCF123×–
FCF yield0.81%–
Fair value$10.20–
Margin of safety−524%–
Growth
Revenue growth (TTM)81.5% (better)36.3%
Revenue growth, 5Y average360% (better)70.2%
Profitability
Gross margin57.9%86.6% (better)
Operating margin15.4% (better)10.9%
Net margin12.0% (better)−5.1%
FCF margin14.0%–
Return on equity36.0%–
Return on invested capital42.5% (better)22.1%
Financial health
Debt / equity0.60–
Net debt / EBITDA0.05 (better)3.45
Interest coverage3.6× (better)1.3×
Current ratio1.52 (better)1.45
Altman Z-score16.19 (better)3.33
Piotroski F-score48 (better)
Dividends and buybacks
Shareholder yield0.00%0.00%
Ownership
Held by institutions74.0%59.4%
Held by insiders5.6%5.2%
Insider net buying, 12 months−$35.0M−$5.8M (better)
Short interest, % of float7.4%5.2%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.